Department of Physiology, The University of Texas Southwestern Medical Center at Dallas, 6001 Forest Park Rd., Dallas, TX 75390, USA.
Mol Neurodegener. 2012 Sep 13;7:45. doi: 10.1186/1750-1326-7-45.
Dopaminergic (DA) neurons in the ventral midbrain selectively degenerate in Parkinson's disease (PD) in part because their oxidative environment in the substantia nigra (SN) may render them vulnerable to neuroinflammatory stimuli. Chronic inhibition of soluble Tumor Necrosis Factor (TNF) with dominant-negative TNF inhibitors protects DA neurons in rat models of parkinsonism, yet the molecular mechanisms and pathway(s) that mediate TNF toxicity remain(s) to be clearly identified. Here we investigated the contribution of ceramide sphingolipid signaling in TNF-dependent toxicity.
Ceramide dose-dependently reduced the viability of DA neuroblastoma cells and primary DA neurons and pharmacological inhibition of sphingomyelinases (SMases) with three different inhibitors during TNF treatment afforded significant neuroprotection by attenuating increased endoplasmic reticulum (ER) stress, loss of mitochondrial membrane potential, caspase-3 activation and decreases in Akt phosphorylation. Using lipidomics mass spectrometry we confirmed that TNF treatment not only promotes generation of ceramide, but also leads to accumulation of several atypical deoxy-sphingoid bases (DSBs). Exposure of DA neuroblastoma cells to atypical DSBs in the micromolar range reduced cell viability and inhibited neurite outgrowth and branching in primary DA neurons, suggesting that TNF-induced de novo synthesis of atypical DSBs may be a secondary mechanism involved in mediating its neurotoxicity in DA neurons.
We conclude that TNF/TNFR1-dependent activation of SMases generates ceramide and sphingolipid species that promote degeneration and caspase-dependent cell death of DA neurons. Ceramide and atypical DSBs may represent novel drug targets for development of neuroprotective strategies that can delay or attenuate the progressive loss of nigral DA neurons in patients with PD.
腹侧中脑中的多巴胺能(DA)神经元在帕金森病(PD)中选择性退化,部分原因是它们在黑质(SN)中的氧化环境可能使它们易受神经炎症刺激。用显性负性肿瘤坏死因子(TNF)抑制剂慢性抑制可溶性 TNF 可保护帕金森病大鼠模型中的 DA 神经元,但介导 TNF 毒性的分子机制和途径仍有待明确确定。在这里,我们研究了神经酰胺鞘脂信号在 TNF 依赖性毒性中的作用。
神经酰胺剂量依赖性地降低了 DA 神经母细胞瘤细胞和原代 DA 神经元的活力,并且在用三种不同抑制剂抑制鞘磷脂酶(SMases)的 TNF 治疗期间进行药理学抑制可通过减轻内质网(ER)应激、线粒体膜电位丧失、半胱天冬酶-3 激活和 Akt 磷酸化减少来提供显著的神经保护作用。使用脂质组学质谱法,我们证实 TNF 处理不仅促进了神经酰胺的产生,而且还导致了几种非典型脱氧鞘氨醇碱基(DSBs)的积累。在微摩尔范围内暴露于非典型 DSB 的 DA 神经母细胞瘤细胞降低了细胞活力并抑制了原代 DA 神经元中的突起生长和分支,这表明 TNF 诱导的非典型 DSB 的从头合成可能是介导其对 DA 神经元神经毒性的次要机制。
我们得出结论,TNF/TNFR1 依赖性激活 SMases 产生神经酰胺和鞘脂物质,促进 DA 神经元的变性和半胱天冬酶依赖性细胞死亡。神经酰胺和非典型 DSB 可能代表新型药物靶点,用于开发神经保护策略,从而延缓或减轻 PD 患者黑质 DA 神经元的进行性丧失。